Soleno Therapeutics
SLNO
About: Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
Employees: 133
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
86% more repeat investments, than reductions
Existing positions increased: 106 | Existing positions reduced: 57
47% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 34
22% more capital invested
Capital invested by funds: $3.9B [Q1] → $4.75B (+$853M) [Q2]
7% more funds holding
Funds holding: 216 [Q1] → 231 (+15) [Q2]
6.38% less ownership
Funds ownership: 118.99% [Q1] → 112.61% (-6.38%) [Q2]
10% less call options, than puts
Call options by funds: $163M | Put options by funds: $181M
16% less funds holding in top 10
Funds holding in top 10: 19 [Q1] → 16 (-3) [Q2]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
|
Guggenheim
Debjit Chattopadhyay
|
$106
|
Buy
Reiterated
|
27 Aug 2025 |
|
Wells Fargo
Derek Archila
|
$123
|
Overweight
Initiated
|
20 Aug 2025 |
|
HC Wainwright & Co.
Raghuram Selvaraju
|
$110
|
Buy
Maintained
|
18 Aug 2025 |
|
Oppenheimer
Leland Gershell
|
$110
|
Outperform
Maintained
|
7 Aug 2025 |
|
Baird
Brian Skorney
|
$121
|
Outperform
Maintained
|
11 Jul 2025 |
Financial journalist opinion
Based on 32 articles about SLNO published over the past 30 days
